1601 TRAPELO ROAD, WALTHAM, MA
Minerva Neurosciences Secures $200M for Roluperidone Phase 3 Trial in Schizophrenia
Other Events
Shareholder votes
Annual Report to Security Holders
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Changes in Board, Management or Compensation
Q3
Q1
Amended Annual Report
FY 2023
Q2
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
SC TO-I
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Correspondence
Submission Upload
Amended Tender Offer Statement by Issuer